Therapy related leukemias: susceptibility, prevention and treatment.
about
Bioflavonoids as poisons of human topoisomerase II alpha and II betaThe emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.Integrated genomics of susceptibility to alkylator-induced leukemia in miceMutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate.Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405.Nutlin-3 enhances sorafenib efficacy in renal cell carcinomaGenetic abnormalities and challenges in the treatment of acute myeloid leukemia.Stem cell transplantation for leukemias following myelodysplastic syndromes or secondary to cytotoxic therapy.Therapy-related, mixed-lineage leukaemia translocation-positive, monoblastic myeloid sarcoma of the uterus.Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.Pharmacogenetics of alkylator-associated acute myeloid leukemia.Quantitative trait loci associated with susceptibility to therapy-related acute murine promyelocytic leukemia in hCG-PML/RARA transgenic miceGingival enlargement as an early diagnostic indicator in therapy-related acute myeloid leukemia: A rare case report and review of literatureThe efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cellsInfluence of DNA damage and repair upon the risk of treatment related leukemia.First-line treatment of follicular lymphoma: a patient-oriented algorithm.Mechanisms of oncogenic chromosomal translocations.Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: Focus on DNA repair genes.Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme.Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma.Therapy-related myeloid neoplasms in patients treated for hodgkin lymphoma.Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell linesSecondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience.PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCERSecondary acute lymphoblastic leukaemia in a multiple myeloma patient.Sequential, cycling maintenance therapy for post transplant multiple myeloma.The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant.Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
P2860
Q24627367-45AD5A5D-DD60-475C-9246-497764311D00Q30252512-9EFCEED4-DEC1-492C-B27C-86D30249D4F4Q33748270-C5FD2D84-3DC4-4767-9599-E45F5B329E36Q33944673-25E906AE-83CD-46C1-95F1-2131AAD84416Q33957966-6B110B46-A422-4B04-BAD7-1B67DD19ACBCQ34127380-FA346ABD-0D95-4052-9E17-13BDFDD563AFQ34631111-D43BDE85-A61E-4EFF-8E62-FA73C4A1280BQ34680950-2DBFB84B-86EB-4EAA-844D-F90CC5EB0898Q36014377-EE1F5C72-1F70-455C-894E-014865A11434Q36194631-8CD0561F-511E-4C08-A117-4ECCCFE46EB4Q36555916-C6010D94-ACF2-4B6E-85CA-977FAEEF8AADQ36835079-D9DDFA41-E519-463A-847C-F456063C9C03Q37020294-87F4511D-6242-4994-B0FB-9664F5405C8CQ37061217-E8C3A947-A7BC-4008-9AD8-4FB9EBAFC593Q37071688-978AEC24-CCB0-4FD0-88C6-A3B15D86489EQ37396916-099A14A7-77AF-4CFB-8EAB-0924EC1845F6Q38188051-9285C66C-AFBC-4528-98C9-0D7EB590455BQ38309335-B7985349-1E65-4691-8EB7-8AA36F8D6EBCQ38679176-601BA0A9-EBA8-49C1-9A9D-F62437884896Q38735518-11219B37-F700-4080-B087-52AD45364E02Q38743262-2A654036-2F7D-4FEB-9C5C-E0238287A2DAQ39209721-9DFE8E43-53D4-46C7-B529-645D368DD462Q39649184-38EC438A-B405-4355-B92A-55B94C7E9EEFQ40040274-9F53ACE5-19E3-4FCF-82D1-29E6C31429ABQ40345824-D26DE905-060C-4122-9B7F-92365302C9DAQ40843669-A9C2AA04-5FA8-43BB-BED6-C88FDD7B9D8BQ43121136-B7FA147A-E9FA-4E08-BD4F-1AB8831D48B9Q46772649-A61BAFCC-7782-4A59-A2B8-69905CC244A0Q47593550-D05B3025-220C-4DD4-8CF5-DAF6FDC1A92EQ53234677-48C763BC-EE7D-4108-851D-348D8721458AQ53462999-3103075D-39B3-40F6-9D29-E71FB03B78D2
P2860
Therapy related leukemias: susceptibility, prevention and treatment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Therapy related leukemias: susceptibility, prevention and treatment.
@ast
Therapy related leukemias: susceptibility, prevention and treatment.
@en
Therapy related leukemias: susceptibility, prevention and treatment.
@nl
type
label
Therapy related leukemias: susceptibility, prevention and treatment.
@ast
Therapy related leukemias: susceptibility, prevention and treatment.
@en
Therapy related leukemias: susceptibility, prevention and treatment.
@nl
prefLabel
Therapy related leukemias: susceptibility, prevention and treatment.
@ast
Therapy related leukemias: susceptibility, prevention and treatment.
@en
Therapy related leukemias: susceptibility, prevention and treatment.
@nl
P2093
P2860
P1433
P1476
Therapy related leukemias: susceptibility, prevention and treatment
@en
P2093
P2860
P304
P356
10.3109/10428190109057981
P577
2001-04-01T00:00:00Z